Great work. The clear objective of making timely progress is reassuring, as is the absence of any adverse reactions (the endpoint of a phase 1 trail).
Ann: Amplia Initiates Multiple Dose Study of AMP945, page-2
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
-0.005(3.70%) |
Mkt cap ! $35.64M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 16.0¢ | 13.0¢ | $830.6K | 5.898M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 206423 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.0¢ | 93793 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| ATX (ASX) Chart |